PMID- 30627842
OWN - NLM
STAT- MEDLINE
DCOM- 20191007
LR  - 20200225
IS  - 1435-1250 (Electronic)
IS  - 0340-1855 (Linking)
VI  - 78
IP  - 4
DP  - 2019 May
TI  - [Current treatment of eosinophilic granulomatosis with polyangiitis 
      (Churg-Strauss syndrome)].
PG  - 333-338
LID - 10.1007/s00393-018-0580-9 [doi]
AB  - For the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) much 
      less data are available when compared to the other anti-neutrophil cytoplasmic 
      antibody (ANCA)-associated vasculitides (AAV). At the same time EGPA also differs 
      in many aspects from AAVs. Treatment is guided by the German and international 
      guidelines. An adapted induction therapy is chosen depending on the disease 
      activity, manifestations and factors determining the prognosis. For patients 
      without negative prognostic factors glucocorticoids alone may be sufficient. A 
      medium potent immunosuppressive agent may be added in order to economize on 
      steroids. For patients with severe organ manifestations and adverse prognostic 
      factors, a highly potent immunosuppression usually with cyclophosphamide, is 
      necessary. In cases of remission a maintenance therapy is recommended in the same 
      way as for other AAVs. Recently, a biological, the IL-5 antibody mepolizumab has 
      also become available, although its precise role still has to be established.
FAU - Moosig, F
AU  - Moosig F
AD  - Rheumazentrum Schleswig-Holstein Mitte, Kuhberg 5a-7, 24534, Neumunster, 
      Deutschland. moosig@rheuma-sh.de.
FAU - Holle, J
AU  - Holle J
AD  - Rheumazentrum Schleswig-Holstein Mitte, Kuhberg 5a-7, 24534, Neumunster, 
      Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Aktuelle Therapie der eosinophilen Granulomatose mit Polyangiitis 
      (Churg-Strauss-Syndrom).
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 90Z2UF0E52 (mepolizumab)
SB  - IM
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/therapy
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - *Churg-Strauss Syndrome/therapy
MH  - Cyclophosphamide/therapeutic use
MH  - *Granulomatosis with Polyangiitis/therapy
MH  - Humans
OTO - NOTNLM
OT  - Biologicals
OT  - Immunosuppression
OT  - Mepolizumab
OT  - Prognosis
OT  - Vasculitis
EDAT- 2019/01/11 06:00
MHDA- 2019/10/08 06:00
CRDT- 2019/01/11 06:00
PHST- 2019/01/11 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
PHST- 2019/01/11 06:00 [entrez]
AID - 10.1007/s00393-018-0580-9 [pii]
AID - 10.1007/s00393-018-0580-9 [doi]
PST - ppublish
SO  - Z Rheumatol. 2019 May;78(4):333-338. doi: 10.1007/s00393-018-0580-9.